How We Measure Portfolio Progress

Veracor reviews its portfolio on two axes rather than one. Financial performance is the first and more familiar. The second is community outcome, meaning whether a business measurably improves access, stability or health where it operates. The firm calls the pairing ROI squared, and it shapes reporting rather than replacing it.

What does Veracor measure in each vertical?

Reviews use a consistent structure with indicators set per vertical, because a housing project and a diagnostics company do not share a meaningful common metric beyond cash.

• Health: patient access, engagement with preventive programs, provider capacity, share of flagged findings that reach a clinician
• Home: units delivered or under development, affordability positioning, occupancy stability, resident retention
• Finance: applications served, approval and servicing quality, borrower education reach, delinquency behavior over time
• Technology: platform adoption across the ecosystem, reliability, security posture, cost per supported company

Why use two axes instead of one?

Because single-axis measurement pushes decisions in predictable directions. Track revenue alone and community outcomes become a marketing exercise attached after the fact. Track outcomes alone and businesses run out of money, which ends the outcomes too. Reporting both forces a company to defend its trade-offs explicitly in front of the people funding it. That argument is the point of the exercise, not a byproduct of it.

How often does reporting happen?

Portfolio companies report to Veracor on a regular internal cycle. Limited partners receive fund-level reporting on the schedule set out in their fund documents. Veracor does not publish company-level financials publicly, and figures shared with investors are unaudited unless a report states otherwise.

How does Veracor handle numbers that are not results yet?

By labeling them. Where a figure is a target, it says target. Where it is a projection, it says projection. Where results are not yet in, the reporting says that instead of substituting an aspiration. This discipline matters more in early-stage investing than in a mature portfolio, because the temptation to describe intent as achievement is highest at the beginning, when there is little else to describe.

What counts as a bad quarter here?

A quarter where a company hits its financial plan by abandoning the thing that made it investable. A health business that grows revenue by increasing procedure volume while patient access declines has not made progress under this framework, even though a single-axis report would show growth. The reverse is also true: a company reaching more people while losing money faster than planned is not on track. Both cases get written up as problems.

How are setbacks communicated?

In the same document as the progress. Portfolio narratives sent to limited partners cover what did not work, including delayed pilots, failed hiring, and partnerships that did not close. Reporting that only contains good news trains investors to distrust all of it.

Who reviews these numbers?

Veracor's investment team reviews every portfolio company on the internal cycle, with vertical leads responsible for the operating indicators in their area and the finance function responsible for the financial ones. Reviews are written rather than presented verbally, because a document can be compared against the previous one and a presentation cannot.

How does measurement change as a company matures?

Early on, almost everything worth tracking is an input: contracts signed, pilots started, clinicians onboarded, units permitted. Those inputs are honest indicators of progress but they are not outcomes, and treating them as outcomes is the most common reporting error in early-stage portfolios. As a company matures, weight shifts toward retention, unit economics and measured effect on the population served. The framework stays the same while the specific indicators move down the chain from activity to result.

What happens when a company misses its plan?

It is written up with the reason, and the reason determines the response. A miss caused by a slow institutional sales cycle is a forecasting problem and calls for a revised plan. A miss caused by a product clinicians will not use is a thesis problem and calls for a harder decision. Veracor separates the two explicitly rather than describing every shortfall as a timing issue.

Can outside parties see these metrics?

Selected aggregate indicators appear on the Outcomes page of this site, with projections marked as projections. Detailed reporting is available to investors under their fund documents. Veracor does not share company-level operating data outside those channels.

Important note

This article describes internal reporting practice and is not investment, legal or tax advice. It is not an offer to sell or a solicitation to buy any security. Metrics, methods and reporting cycles can change.